Oczyesa (octreotide)
- Region
- 🇪🇺 EU
- Active substance
- octreotide
- Company
- Camurus AB
- Status
- Authorised
- Therapeutic area
- Acromegaly
- CHMP opinion
- Fri 25 Apr 2025
- EU approval
- Mon 30 Jun 2025
- Application
- EMEA/H/C/006322
- ATC
- H01CB02
- Official record
- www.ema.europa.eu
Indication
Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mycapssa Withdrawn · Amryt Pharmaceuticals DAC
Follow Oczyesa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.